Eliem Therapeutics (ELYM) Competitors $1.48 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. VYGR, DMAC, BDTX, GALT, IPHA, SLS, ACRS, IMAB, TIL, and PBYIShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Voyager Therapeutics (VYGR), DiaMedica Therapeutics (DMAC), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Innate Pharma (IPHA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), I-Mab (IMAB), Instil Bio (TIL), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Voyager Therapeutics DiaMedica Therapeutics Black Diamond Therapeutics Galectin Therapeutics Innate Pharma SELLAS Life Sciences Group Aclaris Therapeutics I-Mab Instil Bio Puma Biotechnology Eliem Therapeutics (NASDAQ:ELYM) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations. Does the media refer more to ELYM or VYGR? In the previous week, Voyager Therapeutics had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for Eliem Therapeutics. Voyager Therapeutics' average media sentiment score of 0.02 beat Eliem Therapeutics' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eliem Therapeutics Neutral Voyager Therapeutics Neutral Is ELYM or VYGR more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -126.49%. Voyager Therapeutics' return on equity of -27.36% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Voyager Therapeutics -126.49%-27.36%-21.06% Which has better earnings & valuation, ELYM or VYGR? Eliem Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.79Voyager Therapeutics$66.96M2.68-$65M-$1.46-2.22 Do insiders & institutionals believe in ELYM or VYGR? 69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend ELYM or VYGR? Voyager Therapeutics has a consensus price target of $13.39, indicating a potential upside of 313.27%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Voyager Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has more risk & volatility, ELYM or VYGR? Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. SummaryVoyager Therapeutics beats Eliem Therapeutics on 12 of the 16 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.03M$778.65M$5.74B$9.51BDividend YieldN/A4.84%4.60%3.99%P/E Ratio-2.791.4028.1120.03Price / SalesN/A26.88460.63103.88Price / CashN/A19.5636.5559.01Price / Book0.386.798.655.90Net Income-$35.12M-$4.32M$3.25B$258.66M7 Day Performance1.37%1.40%4.20%2.23%1 Month Performance14.73%4.36%10.83%12.77%1 Year Performance-83.37%8.18%34.67%19.36% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.48flatN/A-82.9%$44.03MN/A-2.799Gap DownVYGRVoyager Therapeutics3.8656 of 5 stars$3.17-2.2%$13.39+322.4%-62.8%$179.29M$66.96M-2.17100DMACDiaMedica Therapeutics1.173 of 5 stars$4.54+8.6%$10.75+136.8%+33.7%$179.25MN/A-7.0920High Trading VolumeBDTXBlack Diamond Therapeutics2.9635 of 5 stars$3.15+0.6%$12.80+306.3%-48.7%$177.98MN/A52.5090Positive NewsGALTGalectin Therapeutics2.4432 of 5 stars$2.74-2.1%$6.00+119.0%+14.0%$177.22MN/A-3.819IPHAInnate Pharma2.6261 of 5 stars$1.87-2.9%$11.00+489.8%-10.0%$176.99M$21.77M0.00220Positive NewsGap UpSLSSELLAS Life Sciences Group2.3223 of 5 stars$1.85+4.5%$7.00+278.4%+53.8%$176.61M$1M-4.8710Positive NewsACRSAclaris Therapeutics2.3799 of 5 stars$1.64+1.9%$8.71+431.4%+21.7%$174.33M$17.78M-1.18100Positive NewsGap UpIMABI-Mab2.869 of 5 stars$2.12+1.0%$6.00+183.0%+50.4%$171.49M$3.89M0.00380TILInstil Bio3.1676 of 5 stars$27.62+5.8%$119.00+330.8%+151.7%$171.19MN/A-2.31410Positive NewsPBYIPuma Biotechnology4.233 of 5 stars$3.41+0.3%$7.00+105.3%-8.8%$168.74M$230.50M4.43200Upcoming Earnings Related Companies and Tools Related Companies Voyager Therapeutics Alternatives DiaMedica Therapeutics Alternatives Black Diamond Therapeutics Alternatives Galectin Therapeutics Alternatives Innate Pharma Alternatives SELLAS Life Sciences Group Alternatives Aclaris Therapeutics Alternatives I-Mab Alternatives Instil Bio Alternatives Puma Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELYM Stock Alerts